期刊
ORPHANET JOURNAL OF RARE DISEASES
卷 16, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13023-021-02010-0
关键词
Epidermolysis bullosa; Cannabinoid-based medicines; Symptom alleviation; Patient driven research; Genodermatoses; Survey; Pain; Itch; Wounds
资金
- Epidermolysis Bullosa Research Partnership
The study evaluated the use of cannabinoid-based medicines (CBMs) among EB patients and found that most patients reported a decrease in pain and pruritus after using CBMs, as well as improvements in overall symptoms and wound healing. Additionally, a majority of participants reported reduced use of pain medications. However, further controlled studies are needed to determine the risks and benefits of using CBMs in EB patients.
Background Epidermolysis bullosa (EB) patient anecdotes and case reports indicate that cannabinoid-based medicines (CBMs) may alleviate pain and pruritus and improve wound healing. CBM use has not been characterized in the EB patient population. Objectives To evaluate CBM use among EB patients, including CBM types, effects on symptoms (e.g., pain and pruritus), disease process (e.g., blistering, wounds, and inflammation), well-being (e.g., sleep, appetite) and concomitant medications. Methods English-speaking EB patients or caregivers completed an online international, anonymous, cross-sectional survey regarding CBM use. Respondents reported the types of CBMs, subsequent effects including perceived EB symptom alteration, changes in medication use, and side effects. Results Seventy-one EB patients from five continents reported using or having used CBMs to treat their EB. Missing question responses ranged between 0 (0%) and 33 (46%). Most used more than one CBM preparation (mean: 2.4 +/- 1.5) and route of administration (mean: 2.1 +/- 1.1). Topical and ingested were the most common routes. Pain and pruritus were reported retrospectively to decrease by 3 points (scale: 0-10; p < 0.001 for both) after CBM use. Most reported that CBM use improved their overall EB symptoms (95%), pain (94%), pruritus (91%) and wound healing (81%). Most participants (79%) reported decreased use of pain medications. The most common side-effect was dry mouth (44%). Conclusions CBMs improve the perception of pain, pruritus, wound healing, and well-being in EB patients and reduced concomitant medication use. Nevertheless, a direct relation between the use of CBMs and reduction of the above-mentioned symptoms cannot be proven by these data. Therefore, future controlled studies using pharmaceutically standardised CBM preparations in EB are warranted to delineate the risks and benefits of CBMs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据